AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 13 - (NewsRx.com & NewsRx.net) -- Women with early stage breast cancer treated with a docetaxel-based regimen after surgery had 32% less chance of their cancer returning than women receiving one of the most effective adjuvant - or postsurgery - treatments available.
Results from BCIRG 001, the first phase III study evaluating docetaxel after breast surgery, were presented at the American Society of Clinical Oncology (ASCO) meeting by the Breast Cancer International Research Group (BCIRG).
In the analysis of the study, women were divided into two groups, those with one to three positive lymph nodes and those with four or more. The most significant benefit from the use of docetaxel was seen in women with one to three positive lymph nodes. Among these women, treatment with docetaxel reduced the risk of relapse by 50% and reduced the mortality rate by 54%. Women with one to three positive lymph nodes make up 60-70% of all women worldwide with node-positive early stage breast cancer.
"The superior results observed with the docetaxel-based regimen indicate that it can potentially cure more women than one of the best chemotherapies we have," said Jean-Marc Nabholtz, MD, chairman of the Breast Cancer International Research Group (BCIRG), study chairman, and professor of medicine at the University of California at Los Angeles and Director of the Cancer Therapy Development Program at the Jonsson Comprehensive Cancer Center at UCLA. "Although early, these results should be considered when choosing therapy for a large number of women with early breast cancer."
The BCIRG 001 study was designed to determine if docetaxel, one of the most active agents in advanced breast cancer, would also have benefits for women with early-stage disease. Study participants received either a postsurgery regimen of docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide (Cytoxan), known as TAC, or the widely used standard regimen of 5-fluorouracil, doxorubicin and cyclophosphamide, known as FAC. BCIRG 001 ...